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Abstract
Background: Programmed cell death 4 (Pdcd4) is a novel tumour suppressor and originally
identified as a neoplastic transformation inhibitor. The aim of this study was to investigate the
expression, prognostic significance and potential function of Pdcd4 in ovarian cancer.
Results: The expression of Pdcd4 was examined in 30 normal ovarian tissues, 16 borderline and
93 malignant ovarian tissues. A continuous down regulation of Pdcd4 expression in the sequence
of normal, borderline and malignant tissues was observed. The expressions of Pdcd4 in both
ovarian borderline tissues and carcinomas were significantly lower than the expression in normal
ovarian tissues (p < 0.001). Furthermore, patients with lower Pdcd4 expressions were found to
have shorter disease-free survival (p = 0.037). The expression of Pdcd4 was also assessed by
immunohistochemical analysis in 13 ovarian normal tissues and 44 carcinomas. Different subcellular
localization of Pdcd4 was observed in normal compared to malignant cells. Predominant nuclear
localization of Pdcd4 was found in normal ovarian tissues while ovarian carcinomas showed mainly
cytoplasmic localization of Pdcd4.
Conclusion: Our study demonstrated that the loss of Pdcd4 was a common abnormality at
molecular level in ovarian cancer and it might be a potential prognostic factor in ovarian cancer
patients.
Background
Ovarian cancer is the 5th  commonest cause of cancer
deaths in women in western countries according to the
U.S. cancer statistics [1]. Ovarian cancer patients are often
diagnosed at a late stage, which partially contributes to its
poor prognosis. The mainstay of treatment includes
cytoreductive surgery followed by adjuvant chemother-
apy. Despite optimal primary treatment, recurrences are
common and the overall prognosis is poor. The develop-
ment of novel ovarian cancer diagnostic tests as well as
treatment is urgently required.
Programmed cell death 4 (Pdcd4), a newly identified
tumour suppressor, has been demonstrated to inhibit
tumour promoter-induced neoplastic transformation in
the murine JB6 cell model system [2]. It inhibited AP-1-
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dependent transcriptional activity [3], and directly inter-
acted with and inhibited the helicase activity of eukaryotic
translation initiation factor 4A (eIF4A) by competing its
binding to the scaffold protein eIF4G, thus subsequently
inhibited translation [4]. The human Pdcd4 gene was
localized in chromosome 10q24 [5]. It was expressed in
small duct epithelial cells of the normal mammary gland
[5,6], normal human lung tissue [7], and senescent
human fibroblasts [8]. It was commonly lost in lung can-
cer and such a loss was correlated with higher histological
grade, disease stage and poor prognosis[7]. Expression of
Pdcd4 was found to be reduced in hepatocellular carci-
noma (HCC) [9].
Some studies investigating cellular functions of Pdcd4
demonstrated that it could regulate molecules such as p21
[10], Cdk4, ornithine decarboxylase [11], carbonic anhy-
drase II [12], and JNK/c-Jun/AP-1[13]. It has also been
shown to suppress the expression of the invasion-related
urokinase-receptor-(u-PAR)-gene, and to suppress inva-
sion/intravasation via Sp1/Sp3 promoter motifs in cancer
[14]. The ability of Pdcd4 to suppress colon carcinoma
cell invasion may involve the downregulation of MAP4K1
transcription [15]. Stable expression of antisense Pdcd4
significantly reduced the sensitivity of MCF-7 breast can-
cer cells to geldanamycin and to tamoxifen [16].
Despite the above findings, the roles of Pdcd4 are not uni-
versal. The physiological roles of Pdcd4 in human cancers
are still poorly understood and its role in ovarian cancer
has not been thoroughly investigated. In this study, we
aimed to quantify Pdcd4 mRNA and protein expressions
in human ovarian normal, borderline and malignant tis-
sues and to correlate the expressions with clinical and
pathological parameters, including histology, grade,
stage, disease free and disease specific survival, overall sur-
vival, as well as sensitivity to chemotherapy.
Results
Differential expression patterns of Pdcd4 in normal and 
malignant ovarian cells
Thirteen normal ovarian and 44 ovarian carcinoma paraf-
fin tissue samples were available for immunohistochemi-
cal study. Among these samples, two out of the 13 normal
and 26 out of the 44 malignant tissue samples were a sub-
set of our sample pool for the western blot analysis. Posi-
tive Pdcd4 staining at the ovarian surface epithelium was
observed in 11 out of 13 (84.6%) normal samples and 18
out of 44 (40.9%) carcinomas. Pdcd4 expression in all
normal ovarian epithelial tissues (n = 11) showing posi-
tive staining was localized in nucleus (Figure 1A). On the
other hand, among the cancer tissue samples showing
positive staining, 6 out of 18 (33.3%) displayed nuclear
localization, 9 out of 18 (50%) displayed cytoplasmic
localization (Figure 1B C D E), and 3 out of 18 (16.7%)
displayed both nuclear and cytoplasmic localization.
There was a significant difference in Pdcd4 cellular locali-
zation between normal and cancer tissues (p = 0.002).
Differential Pdcd4 expression levels between normal and 
malignant ovarian tissue samples
Pdcd4 mRNA expressions were assessed in 30 normal, 16
borderline and 93 malignant ovarian samples by real time
quantitative PCR analysis. There was a falling trend in
Pdcd4 mRNA expression in the sequence of normal-bor-
derline-malignant tissues. Pdcd4 mRNA expressions were
significantly lower in malignant tissues (median 3.07,
interquartile range 1.36-5.83) compared to borderline tis-
sues (5.04, 3.95-7.18) (p = 0.041). Pdcd4 mRNA expres-
sions in both malignant and borderline tissues were
significantly lower compared to normal tissues (9.54,
6.25-12.78) (p < 0.001 and p = 0.001 respectively) (Figure
2A).
Pdcd4 protein expressions were assessed by western blot
analysis. Pdcd4 was identified as a main band at around
Representative examples of immunohistochemical staining of  Pdcd4 in ovarian tissues Figure 1
Representative examples of immunohistochemical 
staining of Pdcd4 in ovarian tissues. (A) Distinct nuclear 
staining was found in normal ovarian surface epithelium while 
much weaker cytoplasmic staining was found in (B) serous 
(C) mucinous, (D) endometrioid and (E) poorly differentiated 
adenocarcinomas. Arrows indicated representative positive 
staining sites.Molecular Cancer 2009, 8:70 http://www.molecular-cancer.com/content/8/1/70
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60 kD (Figure 3). A similar falling trend in the sequence
of normal-borderline-malignant tissues was also found in
Pdcd4 protein expression. The expressions in both border-
line (median 0.39, interquartile range 0.21-0.57) and
malignant (0.28, 0.21-0.49) tissues were significantly
lower compared to the expressions in normal ovarian tis-
sues (1.39, 1.15-1.53) (p < 0.001) (Figure 2B). Pdcd4
mRNA expressions correlated with protein expressions
according to western blot analysis (Spearman's rho =
0.515, p < 0.001).
IHC analysis also demonstrated similar results. Among
the eleven normal ovarian samples with positive Pdcd4
expression, five (45.5%) showed strong expression; five
(45.5%) showed moderate expression; one (9.0%)
showed weak expression. On the other hand, among the
nine carcinomas showing exclusive cytoplasmic staining,
four (44.4%) showed moderate expression and five
(55.6%) showed weak expression. Among the six carcino-
mas showing exclusive nuclear staining, one (16.7%)
showed strong expression, two (33.3%) showed moderate
expression and the rest (50%) showed weak expression.
All three carcinomas with both cytoplasmic and nuclear
staining showed weak expression.
Only 28 samples, including two normal and 26 malignant
tissues, had both frozen and paraffin tissues available for
western blot analysis and immunohistochemical staining.
20 out of 28 (71.4%) samples showed concordant results
in both tests (pearson's correlation = 0.455, p = 0.015).
Discordant results were observed in eight samples. Seven
with positive western result showed negative IHC staining
and one sample was vice versa.
Correlation of Pdcd4 expressions with clinical parameters
IHC staining correlated with western blot results, there-
fore, western blot results for Pdcd4 expressions were used
in clinical correlation. For borderline tissues and carcino-
mas (n = 109), clinical data were collected from patients'
records. The median follow-up period was 49 months
(inter quartile range 26-97 months). The disease stages
(stages I-IV) were significantly correlated with disease-free
and overall survival (p < 0.001). Among ovarian cancer
patients with known recurrence status (n = 79), by catego-
rizing Pdcd4 expressions into two levels at median value
(ie, lower expression <= 0.28, higher expression > 0.28),
Pdcd4 was found to be significantly associated with dis-
ease-free survival (log rank = 4.355, p = 0.037) (Figure 4).
Higher Pdcd4 expressions were associated with better dis-
ease free survival of ovarian cancer patients. In multivari-
able analysis using Cox proportional hazards regression
analysis with age, stage of disease, grade and Pdcd4
expression as covariates, Pdcd4 remained as a significant
predictor for disease-free survival (p = 0.007). Apart from
Pdcd4 expression, stage of disease and age were also sig-
nificant independent predictors for disease-free survival
(p = 0.010 and p = 0.027, respectively) (Table 1). Using
the same categorizing criteria, no correlation could be
found between Pdcd4 expression and other clinical
parameters including age, stages of disease, histological
types, grade, metastasis, disease specific and overall sur-
vival (data not shown).
Among 71 ovarian cancer patients treated with platinum
chemotherapy, 68 of them had platinum therapy after
surgery. 55 out of 71 (77.5%) were platinum sensitive and
Differential Pdcd4 mRNA and protein expressions in normal,  borderline and malignant ovarian tissue samples Figure 2
Differential Pdcd4 mRNA and protein expressions in 
normal, borderline and malignant ovarian tissue 
samples. (A) Pdcd4 mRNA expressions were significantly 
lower in malignant (median 3.07, interquartile range 1.36-
5.83) when compared with borderline tissues (5.04, 3.95-
7.18) (p = 0.041), and both malignant and borderline tissues 
showed significant lower expressions than normal tissues 
(9.54, 6.25-12.78) (p < 0.001 and p = 0.001 respectively). (B) 
Pdcd4 protein expressions were significantly lower in both 
borderline (median 0.39, interquartile range 0.21-0.57) and 
malignant (0.28, 0.21-0.49) ovarian cancer tissues when com-
pared with normal tissues (1.39, 1.15-1.53) (p < 0.001).
Western blot analysis of Pdcd4 expression in normal ovarian  and malignant ovarian tissue samples Figure 3
Western blot analysis of Pdcd4 expression in normal 
ovarian and malignant ovarian tissue samples. A rep-
resentative of 8 normal samples (N1-8) and 29 malignant 
samples (C1-29) indicated significant higher Pdcd4 protein 
expression in normal compared with malignant ovarian tissue 
samples. Ovarian cancer cell line C13 or OV2008 were 
included as positive control and β-actin as loading control.Molecular Cancer 2009, 8:70 http://www.molecular-cancer.com/content/8/1/70
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the others were platinum resistant. 31 of 55 (56.4%) plat-
inum sensitive patients had higher Pdcd4 expression
(above median value) and 6 of 16 (37.5%) platinum
resistant patients had higher Pdcd4 expression. There was
no significant difference in the proportion of patients
with higher Pdcd4 expression between the platinum sen-
sitive and resistant groups.
Discussion
In the present study, Pdcd4 mRNA and protein expres-
sions were assessed in a total of 30 normal, 16 borderline
and 93 malignant ovarian tissues. A decreasing trend of
both mRNA and protein expression of Pdcd4 in the
sequence of normal-borderline-malignant ovarian tissue
samples was demonstrated and the expressions of Pdcd4
were significantly reduced in both borderline and malig-
nant samples. This suggested that Pdcd4 might play a role
in human ovarian carcinogenesis. Our results were con-
sistent with the findings in human hepatocellular carci-
noma and lung cancer where loss of Pdcd4 expression was
found in cancer compared with normal tissues [7,9].
However, a study from Yoshinaga et al showed that
increased Pdcd4 expression was detected in bladder can-
cer, suggesting that cell type or tissue specific function of
Pdcd4 may exist [6]. Our data demonstrated a good corre-
lation between Pdcd4 mRNA and protein expression in
ovarian tissue samples (p < 0.001), which was different
from the findings in lung tumours by Kalinichenko and
colleagues [17]. This may be either due to a tissue specific
property of Pdcd4 or the different quantification
approaches between Kalinichenko's and our study, in
which we used real time quantitative PCR instead of con-
ventional semi-quantitative PCR.
Loss of Pdcd4 expression had been demonstrated to cor-
relate with tumour grade, disease stage, recurrence and
patient survival in lung and colorectal cancers [7,18]. In
our study, by classifying Pdcd4 expression into two
groups using median as a cut-off value, we found that
patients with higher Pdcd4 expression had better progno-
sis in terms of disease-free survival, which implied that
Pdcd4 might be a potential prognostic factor to predict the
outcomes of ovarian cancer patients. However, we did not
find any significant correlation between Pdcd4 expression
and overall survival. Since the majority of the death cases
(40 of 43) in our series were tumour related, there was no
significant correlation between Pdcd4 expression and the
disease specific survival either. High Pdcd4 level might
prolong the time to recurrence after initial treatment.
However, once the disease recurred, the protective effect
of Pdcd4 might be limited and other molecular events
could have overtaken, and the tumour somehow becomes
more resistant to the treatment, such as second line chem-
otherapy. This might lead to the non-significant difference
in the overall survival in the two groups. Such specula-
tions would need to be confirmed and the mechanisms
involved would need to be elucidated in future studies.
A study in breast cancer cell line demonstrated knock-
down of Pdcd4 significantly reduced the sensitivity to
geldanamycin and tamoxifen [16]. Therefore, we also
tested whether there was an association between Pdcd4
expression and platinum sensitivity of ovarian cancer. We
chose platinum for our correlation because it was the
most commonly used first line chemotherapy for ovarian
cancer patients. According to our results, no correlation of
Pdcd4 expression and platinum sensitivity could be
found.
Table 1: Cox regression analysis for factors affecting disease free 
survival
79 ovarian cancer patients (median as cut-off value)
Variables Relative risk (95% CI) P value
Age 2.583 (1.114-5.989) 0.027
Grade 1.616 (0.524-2.572) 0.713
Stage of disease 3.487 (1.347-9.022) 0.010
Pdcd4 0.292 (0.120-0.711) 0.007
CI: confidence interval; Coding of variables: Age was coded as 0 (Age 
<= 50) and 1 (Age > 50);
FIGO stage was coded as 0 (stage I and II) and 1(stage III and IV); 
Grade was coded as 0 (grade I and II) and 1(Grade III); Pdcd4 
expression was coded as 0 (Pdcd4 expression <= 0.28) and 1 (Pdcd4 
expression > 0.28).
P value in bold indicated statistical significance.
Influence of Pdcd4 expression on disease-free survival of  ovarian cancer patients Figure 4
Influence of Pdcd4 expression on disease-free sur-
vival of ovarian cancer patients. Pdcd4 expression was 
categorized into lower or higher groups by median value. 
Pdcd4 was significantly associated with disease-free survival 
of ovarian cancer patients (n = 79, p = 0.037).Molecular Cancer 2009, 8:70 http://www.molecular-cancer.com/content/8/1/70
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When this manuscript was being prepared, another study
on Pdcd4 in ovarian cancer by Wang et al was published.
There were a number of differences between their study
and ours. They applied semi-quantitative PCR to measure
Pdcd4 mRNA expression in serous subtype of ovarian can-
cer tissues. Instead, we applied real time PCR which ena-
bled us to detect Pdcd4 mRNA expression more precisely
and we have included various subtypes such as serous,
mucinous, endometrioid, clear cell, etc. They demon-
strated that the loss of Pdcd4 expression was associated
with the progression of serous cystadenocarcinoma [19].
We applied subgroup survival analyses on patients with
serous and endometrioid subtypes. However, no signifi-
cant correlation of Pdcd4 expression with disease free sur-
vival was found (data not shown) when using the median
expression as the cut-off value. The insignificant results
might be due to the smaller sample size in each subgroup.
The number of samples for the other histological types
such as clear cell, mucinous, and mixed type was too small
for individual statistical analysis. Our results demon-
strated that the localization of Pdcd4 in normal tissues
were distinctively in nucleus, which again was different
from their findings.
Several studies have been conducted to investigate the role
of Pdcd4 during tumour progression. Overexpression of
Pdcd4 resulted in inhibition of carcinoid cell proliferation
[20]. The anti-proliferative effect of Pdcd4 was demon-
strated through the repression of transcription of the
mitosis-promoting factor cyclin-dependent kinase
(CDK)1/cdc2 via upregulation of p21Waf1/Cip1 in human
carcinoid cells [10]. Pdcd4 transgenic mice showed lower
tumour incidence and papilloma-to-carcinoma conver-
sion frequency compared with wild-type mice [11]. Pdcd4
was also suggested to be a proapoptotic molecule
involved in TGF beta-1 induced apoptosis in HCC cells
[9]. Diminished Pdcd4 expression deregulated the normal
DNA-damage response thus preventing DNA-damaged
cells from undergoing apoptosis [21]. Using a mouse skin
carcinogenesis model, Schmid et al demonstrated that
Pdcd4 limited tumour formation in vivo, and it was tar-
geted for degradation during tumour promotion [22].
Dorrello's study demonstrated that degradation of Pdcd4
in mitogen-stimulated cells was required for efficient pro-
tein translation thus essential for cell growth or prolifera-
tion [23]. Phosphorylation of Pdcd4 by AKT was essential
for induction of ubiquitin-mediated Pdcd4 degradation
[24]. As it has been suggested that the role of Pdcd4 might
be cell type specific [25], the regulatory mechanisms of
Pdcd4 in ovarian cancer cells still remains to be investi-
gated.
The shuttle of Pdcd4 between nucleus and cytoplasm has
been proposed to have important effect on regulation of
its function. Pdcd4 localized predominantly in nucleus
under normal growth conditions but was exported to the
cytoplasm upon serum withdrawal [26]. A number of
groups have reported the localization of Pdcd4 in differ-
ent cell types. Yoshinaga et al found that Pdcd4 accumu-
lated in the nucleus at the G0 phase of asynchronous
cultures of human normal fibroblasts but was localized in
the cytoplasm during the cell cycle in tumour cell lines
[6]. According to Goke's study, epithelial cells of prostate,
breast and lung disclosed intense nuclear but no cytoplas-
mic staining; a clear shift from nuclear localization to
cytoplasmic staining was observed in all colonic adeno-
mas investigated. In the case of invasive breast cancer tis-
sues, both nuclear and cytoplasmic localization were
observed [10]. As proposed by Zhang [9], the accumula-
tion of Pdcd4 in the nuclei was important for apoptosis,
and the regulatory mechanisms of the localization of
Pdcd4 protein may play an important role in the induc-
tion of apoptosis in HCC cells. In an investigation con-
ducted in colorectal cancer, besides decreased expression
level of Pdcd4, a significant loss of nuclear Pdcd4 from
normal tissues to colonic adenomas and carcinomas was
also observed [18], which again supported the notion that
the intracellular localization of Pdcd4 might play an
important regulatory role in tumour cell progression. In
this study, we also demonstrated similar results with other
groups that a differential expression pattern of Pdcd4 was
found between normal and carcinoma cells by IHC anal-
ysis. Normal ovarian tissue showed distinctive nuclear
staining, whereas majority of cancer tissues displayed
cytoplasmic staining. Our results suggested that Pdcd4
might translocate from the nucleus to the cytoplasm dur-
ing ovarian cancer development. We speculated that the
accumulation of Pdcd4 in the nucleus might negatively
regulate cell proliferation while the cytoplasmic seques-
tration of Pdcd4 might abolish its function in ovarian can-
cer cells. However, this phenomenon needs to be further
confirmed in a larger sample pool, and in-vitro studies
would be needed in order to understand its regulator
mechanism. In conclusion, both localization and expres-
sion level of Pdcd4 might be the potential indicators of
ovarian tumour progression.
Conclusion
Our present study identified Pdcd4 as an ovarian cancer
associated gene based on its differential expression pat-
terns between normal and malignant ovarian samples.
Reduction in Pdcd4 expression correlated with shortened
disease-free survival suggesting that it might have a poten-
tial role in tumour suppressor. In addition, we hypothe-
sized that Pdcd4 might translocate from the nucleus to the
cytoplasm in malignant ovarian tissues. However, the reg-
ulatory mechanisms of Pdcd4 in ovarian tumour progres-
sion remained to be further investigated. Nonetheless, our
study indicated that the loss of Pdcd4 was a common
abnormality at molecular level in ovarian cancer and itMolecular Cancer 2009, 8:70 http://www.molecular-cancer.com/content/8/1/70
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could be a potential prognostic marker in ovarian cancer
patients.
Methods
Sample collection
Ovarian tissues were obtained at the time of surgery
between 1990 and 2006 and snap frozen in liquid nitro-
gen at the Department of Obstetrics and Gynaecology,
Queen Mary Hospital, The University of Hong Kong. A
total of 30 normal, 16 borderline and 93 malignant ovar-
ian tissue samples were randomly selected. The histology
of all the samples was confirmed and the tumour cell con-
tents were at least 70%. The mean age (± standard devia-
tion) of patients with normal ovaries, borderline and
carcinomas were 56 years (± 11.4), 43 years (± 15), and 50
years (± 12), respectively. The histological types and dis-
ease stages were classified according to International Fed-
eration of Gynaecology and Obstetrics (FIGO)
classification. The background characteristics for all the
patients were summarized in Table 2. All 30 normal ovar-
ian samples were obtained from women who had under-
gone hysterectomy for benign diseases.
The use of clinical specimens was approved by the local
institutional ethics committee (institutional review board
reference No: UW 05-143 T/806). Patients with ovarian
cancer were treated according to our unit's protocol which
consisted of total abdominal hysterectomy, bilaterals-
alpinpoophorectomy (BSO) and staging procedure for
early disease, or debulking for advanced disease followed
by adjuvant chemotherapy which consisted of either car-
boplatin alone or in combination with paclitaxel. Disease
free interval was defined as the time from surgery/end of
chemotherapy to either disease progression, recurrence,
death or the last follow-up date of the patients. Response
to platinum therapy was defined as platinum sensitive or
resistant when the recurrence occurred after or within six
months following the completion of therapy respectively.
Patients were considered as platinum refractory if they did
not achieve complete response after the platinum therapy,
and they were also considered as platinum-resistant.
RNA extraction and real time quantitative PCR
Total RNA was extracted from the collected tissues using
TRIZOL® Reagent (Invitrogen corporation, Carlsbad, CA).
cDNA was then synthesized from 1 μg of total RNA using
Superscript III reverse transcriptase (Invitrogen). Pdcd4
mRNA expression was quantitated by real time quantita-
tive RT-PCR (ABI Prism 7500) using power SYBR® Green
PCR Master Mix (Applied Biosystems, Foster, CA) and
specific primers for Pdcd4 (forward: ATGATGTGGAG-
GAGGTGGATGTG; reverse: CCAATGCTAAGGATACT-
GCCAAC). An endogenous control, TATA box Binding
Protein (TBP), was used to normalize Pdcd4 expressions.
The standard curve was constructed from CT values using
5 serial 10-fold dilutions of linearized plasmids of Pdcd4
and TBP, respectively, and the absolute copy numbers of
Pdcd4 mRNA was then determined. All measurements
Table 2: Background characteristics for all recruited ovarian cancer patients
Characteristic Borderline (n = 16) Carcinoma (n = 93)
Age 43 (± 15) 50 (± 12)
stage
1 10 (62.5) 30 (32.2)
2 1 (6.3) 15 (16.1)
3 2 (1.3) 37 (39.8)
4 0 9 (9.7)
unstaged 3 (18.8) 1 (1.1)
unknown stage 1 (1.1)
Histology
Endometrioid 25 (26.9)
Mucinous 13 (81.3) 10 (10.7)
Serous papillary 3(18.7) 29 (31.2)
Clear cell 14 (15.0)
Mixed 12 (12.9)
Undifferentiated 3 (3.2)
Number of recurrences 5 (31.2) 35 (37.6)
Number of persistent disease 0 14 (15.0)
Disease-free interval (months) 49 (30-110) 28 (6-79)
Overall survival time (months) 56 (40-110) 46 (24-97)
With platinum treatment 1 (6.3) 70 (75.3)
Sensitive to platinum 1 (100) 54 (77.1)
Resistant to platinum 16 (22.9)
Without platinum treatment 15 (93.7) 23 (9.1)Molecular Cancer 2009, 8:70 http://www.molecular-cancer.com/content/8/1/70
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were conducted in duplicates. Results for the quantity of
mRNA were expressed as the number of copies of Pdcd4
mRNA per copy of TBP mRNA.
Protein extraction and western blot analysis
Tissue sample proteins were extracted using the conven-
tional method. Briefly, protein extraction RIPA buffer
(NaCl 0.15 M, Tris-HCl 0.05 M, NP-40 1%, DOC 0.005 g/
ml, SDS 0.1%) supplemented with proteinase inhibitor
PMSF 1 mM, Aprotinin 1 ug/ml and Leupeptin 2.5 ug/ml
(Sigma, St Luis, MO) were added to the homogenized tis-
sue samples. Protein lysates were collected after centrifu-
gation and subjected to the subsequent western blot
analysis. Extracts containing 20 ug protein were electro-
phoresed in 10% polyacrylamide-SDS gels and transferred
onto PVDF membranes (Bio-Rad Laboratories, Hercules,
CA). The membrane was blocked with 5% nonfat milk in
TBST (Tris-HCl 5 mM, pH 7.5, NaCl 0.15 M, Tween20
0.1%) at room temperature for one hour and incubated
with affinity purified Pdcd4 antibody (Rockland, Gilberts-
ville, PA) at a dilution of 1:2500 overnight at 4°C. After
intensive wash with TBST, membrane was then incubated
with horseradish peroxidase (HRP) conjugated donkey
anti-rabbit secondary antibodies (Amersham Biosciences,
Buckinghamshire, UK) for one hour at room temperature.
Beta-actin was routinely detected as the internal control
using the beta-actin primary antibody (Sigma) at a 1:5000
dilution and horseradish peroxidase (HRP) conjugated
sheep anti-mouse secondary antibodies (Amersham). The
membrane was then developed by ECL plus (Amersham).
The relative amount of Pdcd4 protein expression was
quantitated by densitometric scanning and normalized by
actin intensity.
Immunohistochemistry
Formalin-fixed and paraffin-embedded clinical samples
were retrieved from the Department of Pathology, Queen
Mary Hospital, The University of Hong Kong. They were
sectioned at 5 μm thick and mounted on aminopropyltri-
ethoxysilane-coated (Sigma, Saint Louis, MO) slides. His-
topathological types were evaluated by pathologists and
the consecutive section was subjected to immunohisto-
chemical staining. Briefly, the slides were deparaffinized,
re-hydrated, and then immersed in distilled water with
3% hydrogen peroxide to suppress endogenous peroxi-
dase activity. Antigen retrieval was performed by micro-
wave treatment in 0.01 M citrate buffer (pH 6.0) for 15
minutes. Sections were incubated with Pdcd4 antibody
(Rockland) at a dilution of 1:100 in 5% normal goat
serum (Zymed Laboratories Inc, South San Francisco, CA)
overnight at 4°C. Envision peroxidase-labeled polymer
(goat-anti-rabbit) (Dako North America Inc, Carpinteria,
CA) was then applied to the sections and signals were
developed by chromogen diaminobenzidine (Amresco
Inc., Salon, OH). The immunoreactivity was estimated
and graded by scoring the percentage of positive nuclear
or cytoplasmic staining (negative, <=5%; weak, 5-19%;
moderate, 20-49%; strong, 50-100%) and intensity of
cytoplasmic staining (negative, weak, moderate, strong).
Statistical analysis
Box plots were used to describe Pdcd4 expression levels in
normal, borderline and malignant ovarian tissue samples
where the box stretched from 25th percentile to 75th per-
centile. A line cross the box indicated the median value,
while error margins indicated the smallest and largest out-
liers. Non parametric Kruskal-Wallis test was used to com-
pare Pdcd4 expression differences among normal,
borderline and carcinomas groups; Mann-Whitney U test
and Wilcoxon signed rank test were used to compare dif-
ferences between two groups. Crosstabs and Pearson Chi-
Square were used to test the correlation between Pdcd4
protein expression and clinical parameters. Non paramet-
ric Spearman's rho's correlation was used to test the corre-
lation of Pdcd4 mRNA and protein expression. Disease
free survival analysis was carried out by Kaplan-Meier and
compared by log rank test. Multivariable analysis (Cox's
regression model) was used to adjust for confounding fac-
tors that might affect the outcome. All statistical analysis
was performed by Statistical Package for Social Science
(SPSS, v13, SPSS Inc., Chicago, IL) and significance was
assumed if p < 0.05.
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